|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Nitroprusside#Contraindications]] |
| {{Nitroprusside}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Contraindications==
| |
| | |
| Sodium nitroprusside should not be used in the treatment of compensatory [[hypertension]], where the primary hemodynamic lesion is aortic coarctation or arteriovenous shunting.
| |
| | |
| Sodium nitroprusside should not be used to produce [[hypotension]] during surgery in patients with known inadequate cerebral circulation, or in moribund patients (A.S.A. Class 5E) coming to emergency surgery.
| |
| | |
| Patients with congenital (Leber’s) optic [[atrophy]] or with tobacco amblyopia have unusually high [[cyanide]]/[[thiocyanate]] ratios. These rare conditions are probably associated with defective or absent rhodanase, and sodium nitroprusside should be avoided in these patients.
| |
| | |
| Sodium nitroprusside should not be used for the treatment of acute congestive [[heart failure]] associated with reduced peripheral vascular resistance such as high-output heart failure that may be seen in endotoxic sepsis.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NITROPRESS (SODIUM NITROPRUSSIDE) INJECTION, SOLUTION, CONCENTRATE [HOSPIRA, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6a44bcac-a0e1-4069-5691-db7b83dbb4b7 | publisher = | date = | accessdate = 27 February 2014 }}</ref>
| |
| | |
| ==References ==
| |
| {{Reflist|2}}
| |
| | |
| {{Nonsympatholytic vasodilatory antihypertensives}}
| |
| | |
| {{DEFAULTSORT:Sodium nitroprusside}}
| |
| [[Category:Cyanides]]
| |
| [[Category:Vasodilators]]
| |
| [[Category:Coordination compounds]]
| |
| [[Category:World Health Organization essential medicines]]
| |
| [[Category:Iron compounds]]
| |
| [[Category:Nitrosyl compounds]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |